Selected research
Industry Research
Smallpox Vaccine Industry Research Report 2026
Market perspective
The global Smallpox Vaccine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Smallpox Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Smallpox Vaccine is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Smallpox Vaccine is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Smallpox Vaccine include CEL-SCI, Chimerix, EpiVax, Nanotherapeutics, Oncovir, SIGA Technologies, Symphogen, TapImmune and Tonix Pharmaceuticals Holding, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Smallpox Vaccine market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Smallpox Vaccine Market by Company
CEL-SCI
Chimerix
EpiVax
Nanotherapeutics
Oncovir
SIGA Technologies
Symphogen
TapImmune
Tonix Pharmaceuticals Holding
Bavarian Nordic
Smallpox Vaccine Segment by Type
First Generation
Second Generation
Third Generation
Smallpox Vaccine Segment by Application
Government Hospital And Program
Private Hospitals / Clinicss
Smallpox Vaccine Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Smallpox Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Smallpox Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Smallpox Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Smallpox Vaccine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Smallpox Vaccine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Smallpox Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- First Generation
- Second Generation
- Third Generation
Applications
- Government Hospital And Program
- Private Hospitals / Clinicss
Companies covered
- CEL-SCI
- Chimerix
- EpiVax
- Nanotherapeutics
- Oncovir
- SIGA Technologies
- Symphogen
- TapImmune
- Tonix Pharmaceuticals Holding
- Bavarian Nordic
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Smallpox Vaccine Market Size (2021-2032)
- 2.2.2 Global Smallpox Vaccine Sales (2021-2032)
- 2.2.3 Global Smallpox Vaccine Market Average Price (2021-2032)
- 2.3 Smallpox Vaccine by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 First Generation
- 2.3.3 Second Generation
- 2.3.4 Third Generation
- 2.4 Smallpox Vaccine by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Government Hospital And Program
- 2.4.3 Private Hospitals / Clinicss
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Smallpox Vaccine Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Smallpox Vaccine Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Smallpox Vaccine Revenue of Manufacturers (2021-2026)
- 3.4 Global Smallpox Vaccine Average Price by Manufacturers (2021-2026)
- 3.5 Global Smallpox Vaccine Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Smallpox Vaccine, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Smallpox Vaccine, Product Type & Application
- 3.8 Global Manufacturers of Smallpox Vaccine, Established Date
- 3.9 Global Smallpox Vaccine Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 CEL-SCI
- 4.1.1 CEL-SCI Company Information
- 4.1.2 CEL-SCI Business Overview
- 4.1.3 CEL-SCI Smallpox Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 CEL-SCI Smallpox Vaccine Product Portfolio
- 4.1.5 CEL-SCI Recent Developments
- 4.2 Chimerix
- 4.2.1 Chimerix Company Information
- 4.2.2 Chimerix Business Overview
- 4.2.3 Chimerix Smallpox Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Chimerix Smallpox Vaccine Product Portfolio
- 4.2.5 Chimerix Recent Developments
- 4.3 EpiVax
- 4.3.1 EpiVax Company Information
- 4.3.2 EpiVax Business Overview
- 4.3.3 EpiVax Smallpox Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 EpiVax Smallpox Vaccine Product Portfolio
- 4.3.5 EpiVax Recent Developments
- 4.4 Nanotherapeutics
- 4.4.1 Nanotherapeutics Company Information
- 4.4.2 Nanotherapeutics Business Overview
- 4.4.3 Nanotherapeutics Smallpox Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Nanotherapeutics Smallpox Vaccine Product Portfolio
- 4.4.5 Nanotherapeutics Recent Developments
- 4.5 Oncovir
- 4.5.1 Oncovir Company Information
- 4.5.2 Oncovir Business Overview
- 4.5.3 Oncovir Smallpox Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Oncovir Smallpox Vaccine Product Portfolio
- 4.5.5 Oncovir Recent Developments
- 4.6 SIGA Technologies
- 4.6.1 SIGA Technologies Company Information
- 4.6.2 SIGA Technologies Business Overview
- 4.6.3 SIGA Technologies Smallpox Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 SIGA Technologies Smallpox Vaccine Product Portfolio
- 4.6.5 SIGA Technologies Recent Developments
- 4.7 Symphogen
- 4.7.1 Symphogen Company Information
- 4.7.2 Symphogen Business Overview
- 4.7.3 Symphogen Smallpox Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Symphogen Smallpox Vaccine Product Portfolio
- 4.7.5 Symphogen Recent Developments
- 4.8 TapImmune
- 4.8.1 TapImmune Company Information
- 4.8.2 TapImmune Business Overview
- 4.8.3 TapImmune Smallpox Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 TapImmune Smallpox Vaccine Product Portfolio
- 4.8.5 TapImmune Recent Developments
- 4.9 Tonix Pharmaceuticals Holding
- 4.9.1 Tonix Pharmaceuticals Holding Company Information
- 4.9.2 Tonix Pharmaceuticals Holding Business Overview
- 4.9.3 Tonix Pharmaceuticals Holding Smallpox Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Tonix Pharmaceuticals Holding Smallpox Vaccine Product Portfolio
- 4.9.5 Tonix Pharmaceuticals Holding Recent Developments
- 4.10 Bavarian Nordic
- 4.10.1 Bavarian Nordic Company Information
- 4.10.2 Bavarian Nordic Business Overview
- 4.10.3 Bavarian Nordic Smallpox Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Bavarian Nordic Smallpox Vaccine Product Portfolio
- 4.10.5 Bavarian Nordic Recent Developments
5 Global Smallpox Vaccine Market Scenario by Region
- 5.1 Global Smallpox Vaccine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Smallpox Vaccine Sales by Region: 2021-2032
- 5.2.1 Global Smallpox Vaccine Sales by Region: 2021-2026
- 5.2.2 Global Smallpox Vaccine Sales by Region: 2027-2032
- 5.3 Global Smallpox Vaccine Revenue by Region: 2021-2032
- 5.3.1 Global Smallpox Vaccine Revenue by Region: 2021-2026
- 5.3.2 Global Smallpox Vaccine Revenue by Region: 2027-2032
- 5.4 North America Smallpox Vaccine Market Facts & Figures by Country
- 5.4.1 North America Smallpox Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Smallpox Vaccine Sales by Country (2021-2032)
- 5.4.3 North America Smallpox Vaccine Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Smallpox Vaccine Market Facts & Figures by Country
- 5.5.1 Europe Smallpox Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Smallpox Vaccine Sales by Country (2021-2032)
- 5.5.3 Europe Smallpox Vaccine Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Smallpox Vaccine Market Facts & Figures by Country
- 5.6.1 Asia Pacific Smallpox Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Smallpox Vaccine Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Smallpox Vaccine Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Smallpox Vaccine Market Facts & Figures by Country
- 5.7.1 South America Smallpox Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Smallpox Vaccine Sales by Country (2021-2032)
- 5.7.3 South America Smallpox Vaccine Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Smallpox Vaccine Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Smallpox Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Smallpox Vaccine Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Smallpox Vaccine Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Smallpox Vaccine Sales by Type (2021-2032)
- 6.1.1 Global Smallpox Vaccine Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Smallpox Vaccine Sales Market Share by Type (2021-2032)
- 6.2 Global Smallpox Vaccine Revenue by Type (2021-2032)
- 6.2.1 Global Smallpox Vaccine Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Smallpox Vaccine Revenue Market Share by Type (2021-2032)
- 6.3 Global Smallpox Vaccine Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Smallpox Vaccine Sales by Application (2021-2032)
- 7.1.1 Global Smallpox Vaccine Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Smallpox Vaccine Sales Market Share by Application (2021-2032)
- 7.2 Global Smallpox Vaccine Revenue by Application (2021-2032)
- 7.2.1 Global Smallpox Vaccine Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Smallpox Vaccine Revenue Market Share by Application (2021-2032)
- 7.3 Global Smallpox Vaccine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Smallpox Vaccine Value Chain Analysis
- 8.1.1 Smallpox Vaccine Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Smallpox Vaccine Production Mode & Process
- 8.2 Smallpox Vaccine Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Smallpox Vaccine Distributors
- 8.2.3 Smallpox Vaccine Customers
9 Global Smallpox Vaccine Analyzing Market Dynamics
- 9.1 Smallpox Vaccine Industry Trends
- 9.2 Smallpox Vaccine Industry Drivers
- 9.3 Smallpox Vaccine Industry Opportunities and Challenges
- 9.4 Smallpox Vaccine Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst